Different clones, protocol conditions, instruments, and scoring/readout methods may pose
challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic …

Immunotherapy, based on immune checkpoint inhibitors (ICIs) targeting the programmed
cell death ligand 1 (PD-L1) and/or programmed death receptor 1 (PD-1), has substantially …

Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on
certain lymphocytes that, with its ligand programmed death ligand 1 (PD-L1), helps to down …

Abstract Background Programmed Death Ligand 1 (PD-L1) is an immune modulating
protein expressed on the surface of various inflammatory cells, including T Cells, B Cells …

Abstract Programmed death 1 ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-
approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

PURPOSE Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8,
22C3, SP263, and SP142) have been approved for use by the US Food and Drug …

Abstract Objectives The Blueprint (BP) Programmed Death Ligand 1 (PD-L1)
Immunohistochemistry Comparability Project is a pivotal academic/professional society and …

Background For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is
limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) …

Targeting of the PD1/PD-L1 immune checkpoint pathway has rapidly gained acceptance as
a therapeutic strategy for a growing number of malignancies. Testing for expression of PD …